Page 1 of 1

Wuxi Biologics 2269

PostPosted: Thu Oct 22, 2020 3:25 pm
by winston
not vested

Wuxi Biologics (2269 HK) - Guidance raised

Wuxi Biologics is a leading global open-access biologics technology platform offering end-to-end solutions services to support global corporate clients in the development process of discovery, development and manufacturing of biologics.

The company is the first Chinese biologics company approved by both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), and operates multiple world class Good Manufacturing Practices (GMP) manufacturing facilities for biologics production.

Its estimated market shares are ~78.6% (China) and ~5.1% globally (behind global peers such as Lonza and IQVIA).

Key strengths include its multiple leading platforms, expertise to conduct clinical trials, solid execution and track record, and lower labour costs which have helped in project wins and customer stickiness.

Despite the pandemic impact on the business in 1H20, 2020 should still close with meaningful growth supported by new Covid-19 related projects the company clinched due to its quick response time and premier technology platforms.

Being in a growth phase with meaningful expansion plans, the company does not pay dividends. BUY.

Source: OCBC

Re: Wuxi Biologics 2269

PostPosted: Mon Jul 05, 2021 11:22 am
by winston
not vested

Wuxi Biologics (2269 HK) - Investor day highlights

Wuxi Biologics is a leading global open-access biologics technology platform offering end-to-end solutions services to support global corporate clients in the development process of discovery, development and manufacturing of biologics.

The company is the first Chinese biologics company approved by both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), and operates multiple world class Good Manufacturing Practices (GMP) manufacturing facilities for biologics production.

Its estimated market shares are ~78.6% (China) and ~5.1% globally (behind global peers such as Lonza and IQVIA).

Key strengths include its multiple leading platforms, expertise to conduct clinical trials, solid execution and track record, and lower labour costs which have helped in project wins and customer stickiness.

Despite the pandemic impact on the business in 1H20, 2020 should still close with meaningful growth supported by new Covid-19 related projects the company clinched due to its quick response time and premier technology platforms.

Being in a growth phase with meaningful expansion plans, the company does not pay dividends. BUY.

Source: OCBC

Re: Wuxi Biologics 2269

PostPosted: Mon Oct 04, 2021 4:22 pm
by winston
not vested

WUXI BIO(2269)

Analysis:

WUXI Biologics (2269) continues to offer end-to-end solutions to accelerate and transform the discovery, development, and manufacturing of biologics, and in particular COVID-19 treatments and vaccines, through the successful implementation of the “Win-the-Molecule” strategy.

The Group provided services to 352 customers for the six months ended June 30, 2021, compared with 264 customers for the same period last year.

It worked with 18 out of the 20 largest pharmaceutical companies in the world and 36 out of the 50 largest pharmaceutical companies in China.

The Group`s total backlog , including the service backlog and upcoming potential milestone fees backlog, increased by 31.7% from US$9,464 million as of June 30, 2020 to US$12,465 million as of June 30, 2021. (I do not hold the above stock)

Strategy:
Buy-in Price: $124, Target Price: $142, Cut Loss Price: $116

Source: Phillips

Re: Wuxi Biologics 2269

PostPosted: Wed Feb 09, 2022 4:53 pm
by winston
not vested

Jefferies: Still Highly Confident in WUXI BIO, Price Correction Golden Chance to Accumulate

WUXI BIO (02269.HK) was predicted to be sufficiently capable in resolving issues that may arise following the inclusion of two of its subsidiaries, namely WuXi Biologics Co., Ltd. and WuXi Biologics (Shanghai) Co., Ltd., in the Unverified List (UVL), reported Jefferies.

The broker remained highly confident in WUXI BIO, describing the share price correction in the past two days as a golden opportunity for the investors to accumulate the stock.

The stock's rating was restated at Buy, with a target price of $200.

Related Newszzz: C Suisse Trims WUXI BIO (02269.HK) TP to $120; Rated Outperform

Jefferies suggested that, subsidiaries of WUXI BIO may have been added to the UVL because the U.S. were unable to verify the ultimate usage of the purchased materials.

If the companies carry out relevant corrections, including submitting written proof, they could be removed from the list, the broker added.

Source: AAStocks Financial News

Re: Wuxi Biologics 2269

PostPosted: Thu Feb 10, 2022 3:13 pm
by winston
not vested

Daiwa Downgrades WUXI BIO (02269.HK) to Outperform with TP Slashed to $75

While the inclusion of WuXi Biologics Co., Ltd. and WuXi Biologics (Shanghai) Co., Ltd., both being subsidiaries of WUXI BIO (02269.HK), in the Unverified List (UVL), was estimated to pose only minor impact on the group's daily operations, the uncertainty of the company being added to other lists continues to linger, reported Daiwa.

Given that the North America operations of WUXI BIO accounts for up to 50% of its total revenues, such uncertainty will likely severely damage the market sentiment and may lead to continual de-rating, Daiwa remarked.

The broker, therefore, downgraded the stock from Buy to Outperform, with its target price slashed from $167 to $75.

Related News: WUXI BIO Foretells FY21 NP to Surge Over 98% YoY

Source: AAStocks Financial News